<p><strong>Pediatric Use</strong>: Safety and effectiveness have not been established in pediatric patients less than 1 year of age.<br />
<br />
<strong>Geriatric Use</strong>: No relevant pharmacokinetic differences have been observed in elderly (&gt;65 years) or very elderly (&gt;75 years) patients compared to the overall population.<br />
&nbsp;<br />
<strong>Hepatic Impairment</strong>: No dose adjustment is required when administering this tablet&nbsp;to patients with mild hepatic impairment (Child-Pugh A classification). This tablet&nbsp;is not recommended in patients with severe hepatic impairment, as no studies have been conducted in these patients.<br />
<br />
<strong>Renal Impairment</strong>: No dose adjustment is required in patients with mild (eGFR 60 to 90 ml/min/1.73 m2) to moderate (eGFR 30 to 60 ml/min/1.73 m2) renal impairment. The recommended starting dose in patients with severe renal impairment (eGFR &lt;30 ml/min/1.73 m2) is 24/26 mg twice daily.</p>